<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05013697</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-II-13</org_study_id>
    <nct_id>NCT05013697</nct_id>
  </id_info>
  <brief_title>TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.</brief_title>
  <official_title>A Multicenter Exploratory Study of Paclitaxel+Cisplatin+TQB2450 Injection Combined With or Without Anlotinib in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Henan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The regimen of paclitaxel+cisplatin+TQB2450 injection combined or not combined with anlotinib&#xD;
      is the first-line treatment of advanced esophageal squamous cell carcinoma. Take PFS as the&#xD;
      main evaluation index, the purpose is to evaluate its effectiveness and safety&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS， RECIST assessment)</measure>
    <time_frame>each 42 days（Initial treatment） or 63 days ( Maintenance treatment) up to Progressive Disease or Intolerable toxicity （Up to 24 months）</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (iPFS)</measure>
    <time_frame>each 42 days（Initial treatment） or 63 days ( Maintenance treatment) up to Progressive Disease or Intolerable toxicity （Up to 24 months）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>each 42 days（Initial treatment） or 63 days ( Maintenance treatment) up to Progressive Disease or Intolerable toxicity （Up to 24 months）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR）</measure>
    <time_frame>each 42 days（Initial treatment） or 63 days ( Maintenance treatment) up to Progressive Disease or Intolerable toxicity （Up to 24 months）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>each 42 days（Initial treatment） or 63 days ( Maintenance treatment) up to Progressive Disease or Intolerable toxicity （Up to 24 months）</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-related adverse Events</measure>
    <time_frame>Through study completion, an average of 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Experimental group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib (4-6 cycles).&#xD;
Maintenance treatment: TQB2450 injection+Anlotinib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial treatment: Paclitaxel + Cisplatin + TQB2450 injection (4-6 cycles). Maintenance treatment: TQB2450 injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib</intervention_name>
    <description>TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14；Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.</description>
    <arm_group_label>Experimental group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel + Cisplatin + TQB2450 injection</intervention_name>
    <description>TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection（1200 mg, i.v.gtt , d1）. The regimen is repeated every 3 weeks until the disease progresses.</description>
    <arm_group_label>Experimental group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell carcinoma of the esophagus,&#xD;
             locally advanced, unresectable, recurrent or metastatic disease.&#xD;
&#xD;
          -  Those who have not received systemic treatment before, or who relapsed after (new)&#xD;
             adjuvant therapy/radical surgery more than 6 months ; Note: Including advanced or&#xD;
             recurrent Patients who ever received only radiotherapy on non-target lesions. The&#xD;
             duration from the end of palliative treatment for local lesions (non-target lesions)&#xD;
             to enrollment should &gt; 2 weeks;&#xD;
&#xD;
          -  According to RECIST 1.1, at least one measurable lesion; the measurable lesions should&#xD;
             not have received local treatment such as radiotherapy (for the lesions in the area&#xD;
             where received local radiotherapy, it can also be regarded as a target lesion if&#xD;
             confirmed to progress according to the recist1.1);&#xD;
&#xD;
          -  18 and 75 years old;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1；Life expectancy&#xD;
             of at least 3 months.&#xD;
&#xD;
          -  the main organ function to meet the following criteria:&#xD;
&#xD;
             (1)Blood routine tests met the following requirements:&#xD;
&#xD;
             a) haemoglobin(HB)≥90g/L ； b) absolute neutrophil count(NEUT)≥1.5×109/L ； c) platelet&#xD;
             count(PLT)≥100×109/L；&#xD;
&#xD;
             （2） Biochemical tests met the following requirements： total bilirubin(TBIL)≤ 1.5 times&#xD;
             the upper limit of normal (ULN) .≤5 × ULN if with liver involvement； serum creatinine&#xD;
             ≤1.5 × the ULN or creatinine clearance≥50mL/min。&#xD;
&#xD;
             （3） Coagulation or thyroid function meet the following criteria: International&#xD;
             Normalized Ratio (INR) ≤1.5 and Partial Thromboplastin Time (PT) or activated PTT&#xD;
             (APTT) ≤1.5 × (ULN)).&quot;&#xD;
&#xD;
          -  Male or female subjects should agree to use an adequate method of contraception&#xD;
             starting with the first dose of study therapy through 3 months after the last dose of&#xD;
             study&#xD;
&#xD;
          -  The patient volunteers to participate in the study, signs a consent form, has good&#xD;
             compliance, and obeys the follow-up, and is willing and able to follow the protocol&#xD;
             during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients tends to have complete obstruction or patients requiring interventional&#xD;
             treatment for obstruction;&#xD;
&#xD;
          -  Patients with a high risk of bleeding or perforation due to the apparent invasion of&#xD;
             adjacent organs (aorta or trachea) of the esophageal lesion, or patients who have&#xD;
             formed fistulas;&#xD;
&#xD;
          -  Patients with symptoms of hematemesis, hematochezia and daily bleeding ≥ 2.5 mL, or&#xD;
             any bleeding event with Common Terminology Criteria for Adverse Events （CTCAE） level 3&#xD;
             within 3 months before screening;&#xD;
&#xD;
          -  allergic to study drugs 、paclitaxel and cisplatin preparations or excipients;&#xD;
&#xD;
          -  Adjuvant chemotherapy patients who have used paclitaxel or cisplatin, and relapse or&#xD;
             metastasize within one year&#xD;
&#xD;
          -  A variety of factors affecting oral medications (such as inability to swallow, chronic&#xD;
             diarrhea, and intestinal obstruction);&#xD;
&#xD;
          -  patients with any severe and / or uncontrolled disease, including:Unsatisfactory blood&#xD;
             pressure control using antihypertensive drugs (systolic blood pressure ≥150 mmhg or&#xD;
             diastolic blood pressure ≥100) Mmhg) patients; patients with grade ≥ myocardial&#xD;
             ischemia or myocardial infarction, arrhythmia (including qt interval ≥ 480ms);&#xD;
             according to nyha criteria, iii-iv cardiac dysfunction, or cardiac ultrasonography&#xD;
             prompted left ventricular ejection fraction (lvef) &lt;50% of patients;live Severe&#xD;
             infection that is sexual or uncontrolled;Liver diseases such as cirrhosis,&#xD;
             decompensated liver disease, chronic active hepatitis;poor diabetes control (fasting&#xD;
             blood glucose (fbg)&gt;10mmol/l);Urine routine indicates that urine protein ≥ ++, and&#xD;
             confirmed 24-hour urine protein quantitation &gt; 1.0 g&#xD;
&#xD;
          -  long-term unhealed wounds or fractures;&#xD;
&#xD;
          -  Patients with active hemorrhage within 2 months of primary lesions; pulmonary&#xD;
             hemorrhage with NCI CTCAE grade &gt;1, 4 weeks before of enrollment; other sites of&#xD;
             bleeding NCI CTCAE grade &gt;2, 4 weeks before of enrollment; patients with bleeding&#xD;
             tendency (such as active gastrointestinal ulcers) or patients undergoing thrombolytic&#xD;
             or anticoagulant therapy such as warfarin, heparin or its analogues;&#xD;
&#xD;
          -  Have undergone major surgery (craniotomy, thoracotomy or open surgery) within 4 weeks&#xD;
             prior to the first dose study or Major surgery is required during the study period.&#xD;
&#xD;
          -  A history of gastrointestinal perforation and/or fistula occurred within 6 months&#xD;
             prior to treatment; or an overactive/venous thrombosis event such as a cerebrovascular&#xD;
             accident (including transient ischemic attack), deep vein thrombosis, and lung&#xD;
             Embolism；&#xD;
&#xD;
          -  Symptomatic central nervous system metastasis and/or cancerous meningitis are known to&#xD;
             exist;&#xD;
&#xD;
          -  Clinically significant ascites, including any ascites that can be found on a physical&#xD;
             examination, ascites that has been treated or currently in need of treatment, and only&#xD;
             those with a small amount of ascites but no symptoms can be selected;&#xD;
&#xD;
          -  A moderate amount of fluid in both sides of the chest, or a large amount of fluid in&#xD;
             one side of the chest, or has caused respiratory dysfunction Patient to be drained;&#xD;
&#xD;
          -  known to have active tuberculosis;&#xD;
&#xD;
          -  suffering from interstitial lung disease requiring steroid therapy;&#xD;
&#xD;
          -  Uncontrolled metabolic disorders or other non-malignant tumors or systemic diseases or&#xD;
             cancer secondary reactions that can lead to higher medical risks and/or survival&#xD;
             Evaluation of uncertainty;&#xD;
&#xD;
          -  Significantly malnourished patients;&#xD;
&#xD;
          -  those who have a history of psychotropic substance abuse and are unable to quit or&#xD;
             have a mental disorder;&#xD;
&#xD;
          -  A history of immunodeficiency, including a positive HIV test or other acquired,&#xD;
             congenital immunodeficiency disease, or a history of organ transplantation;&#xD;
&#xD;
          -  History of other primary malignancies, but the following : 1) complete remission of&#xD;
             malignant tumors for at least 2 years prior to enrollment and no additional treatment&#xD;
             during the study; 2) non-melanoma skin cancer or malignant freckle-like sputum with&#xD;
             adequate treatment and no evidence of disease recurrence; 3) adequately treated and In&#xD;
             situ carcinoma without evidence of disease recurrence;&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding;&#xD;
&#xD;
          -  According to the judgment of the investigator, there is a concomitant disease that&#xD;
             seriously endangers the safety of the patient or affects the completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suxia Luo, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Henan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suxia Luo, Doctor</last_name>
    <phone>0371-65587697</phone>
    <email>2290773710@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AnYang Tumor Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junsheng Wang, Undergraduate</last_name>
      <phone>13503723589</phone>
      <email>1207741934@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The People's Hospital Of AnYang City</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Heming Xi, Undergraduate</last_name>
      <phone>13603729033</phone>
      <email>xiheming2013@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Henan University of Science and Technolog</name>
      <address>
        <city>Luoyang</city>
        <state>Henan</state>
        <zip>471000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanzhen Guo, Undergraduate</last_name>
      <phone>13937903068</phone>
      <email>guoyanzhen177@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianwei Zhou, Doctor</last_name>
      <phone>13937120756</phone>
      <email>drzhoujw@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Suxia Luo, Doctor</last_name>
      <phone>0371-65587697</phone>
      <email>2290773710@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Ning Li, Doctor</last_name>
      <phone>13526501903</phone>
      <email>lining97@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, Zhai J, Mai S, Jiang J, Wang Z, Wu H, Cai K. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. J Immunol Res. 2019 Nov 4;2019:1919082. doi: 10.1155/2019/1919082. eCollection 2019. Review.</citation>
    <PMID>31781673</PMID>
  </reference>
  <reference>
    <citation>Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017 May;20(2):185-204. doi: 10.1007/s10456-017-9552-y. Epub 2017 Mar 30. Review.</citation>
    <PMID>28361267</PMID>
  </reference>
  <reference>
    <citation>[1]He Jie, Shao Kang. The epidemiology, diagnosis and treatment of esophageal cancer in China and future strategies[J]. Chinese Journal of Cancer, 2011, 21(07): 501-504.</citation>
  </reference>
  <results_reference>
    <citation>Gandini S, Massi D, Mandalà M. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2016 Apr;100:88-98. doi: 10.1016/j.critrevonc.2016.02.001. Epub 2016 Feb 10. Review.</citation>
    <PMID>26895815</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen W, Sun K, Zheng R, Zeng H, Zhang S, Xia C, Yang Z, Li H, Zou X, He J. Cancer incidence and mortality in China, 2014. Chin J Cancer Res. 2018 Feb;30(1):1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01.</citation>
    <PMID>29545714</PMID>
  </results_reference>
  <results_reference>
    <citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313.</citation>
    <PMID>30207593</PMID>
  </results_reference>
  <results_reference>
    <citation>Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines for Diagnosis and Treatment of Esophageal Cancer (2021 Edition) [M]. Beijing: People's Medical Publishing House, 2021.</citation>
  </results_reference>
  <results_reference>
    <citation>Blot, W. J. &amp; Tarone, R. E. Esophageal cancer. Nat Rev Dis Prim. 3, 17048 (2017).</citation>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 12, 2021</study_first_submitted>
  <study_first_submitted_qc>August 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

